Initial studies on squalene from some marine microalgae isolated in Vietnam

Ngọc, Đinh Thị; Ha, Nguyen Cam; Thom, Le Thi; Hồng, Đặng Diễm

doi:10.15625/0866-7160/v35n3.3386

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several heterotrophic marine microorganisms are strong DHA producers, such as the dinoflagellate Crypthecodinium cohnii (Dinophyceae) and, above all, the thraustochytrids protists Thraustochytrium spp., Aurantiochytrium (formerly Schizochytrium) limacinum (Labyrinthulomycetes) [129][130][131][132][133], and related genera [134]. Although these microorganisms cannot exploit light energy to drive their metabolism, they are capable of fermenting plant biomass hydrolysates, affording cost-effective heterotrophic cultivation using renewable feedstocks [135][136][137][138][139][140][141].…”

Section: Long-chain Polyunsaturated Fatty Acidsmentioning

confidence: 99%

The Clinical Promise of Microalgae in Rheumatoid Arthritis: From Natural Compounds to Recombinant Therapeutics

Cutolo,

Caferri,

Campitiello

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an invalidating chronic autoimmune disorder characterized by joint inflammation and progressive bone damage. Dietary intervention is an important component in the treatment of RA to mitigate oxidative stress, a major pathogenic driver of the disease. Alongside traditional sources of antioxidants, microalgae—a diverse group of photosynthetic prokaryotes and eukaryotes—are emerging as anti-inflammatory and immunomodulatory food supplements. Several species accumulate therapeutic metabolites—mainly lipids and pigments—which interfere in the pro-inflammatory pathways involved in RA and other chronic inflammatory conditions. The advancement of the clinical uses of microalgae requires the continuous exploration of phytoplankton biodiversity and chemodiversity, followed by the domestication of wild strains into reliable producers of said metabolites. In addition, the tractability of microalgal genomes offers unprecedented possibilities to establish photosynthetic microbes as light-driven biofactories of heterologous immunotherapeutics. Here, we review the evidence-based anti-inflammatory mechanisms of microalgal metabolites and provide a detailed coverage of the genetic engineering strategies to enhance the yields of endogenous compounds and to develop innovative bioproducts.

show abstract